Impacted Third MolarNCT07320170
Comparative Effects of CGF and PRP in Impacted Third Molar Surgery
A study testing Concentrated Growth Factor (CGF) and Platelet-Rich Plasma (PRP) in people with Impacted Third Molar, run by Recep Tayyip Erdogan University at 1 site in Turkey (Türkiye).
Trial summary
This study evaluates the effects of two different blood products obtained from the patient's own blood (Concentrated Growth Factor [CGF] and Platelet-Rich Plasma [PRP]) on healing after wisdom tooth extraction. Read more about this study
- Who is it for?
- Ages 18 to 50 years
- Conditions the study is for
- Impacted Third Molar
- What is being tested?
- Concentrated Growth Factor (CGF) and Platelet-Rich Plasma (PRP)
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 42 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 2 May 2024to 2 May 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Patients aged between 18 and 50 years.
- Systemically healthy individuals classified as American Society of Anesthesiologists (ASA) Class I or Class II.
- Presence of impacted mandibular third molars (teeth 38 and 48 according to Fédération Dentaire Internationale (FDI) notation).
- Mesioangular impaction with bone retention according to Winter's classification.
- Class II relationship to the ramus according to the Pell and Gregory classification.
- Level B or Level C depth of impaction according to the Pell and Gregory classification.
Who cannot join
- Patients younger than 18 years.
- Habitual smoking or alcohol consumption.
- Presence of coagulation (bleeding) disorders.
- Systemic diseases affecting wound healing or use of medications that compromise healing.
- Pregnancy or lactation.
- Presence of active pericoronitis associated with the tooth.
Show all 10Show fewer
- Presence of pathological lesions (cysts or tumors) associated with the impacted tooth.
- Uncontrolled periodontal disease in the oral cavity.
- Known allergy to any medications used in the study protocol.
- Inability to comply with follow-up visits.
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Recep Tayyip Erdogan University, Faculty of Dentistry
Rize
About this study
Official title: Evaluation of the Effects of Platelet-rich Plasma and Concentrated Growth Factor on Postoperative Pain, Swelling, and Alveolar Osteitis After Mandibular Third Molar Surgery: a Randomized Controlled Clinical Trial
This study evaluates the effects of two different blood products obtained from the patient's own blood (Concentrated Growth Factor [CGF] and Platelet-Rich Plasma [PRP]) on healing after wisdom tooth extraction. The aim is to determine whether applying these materials to the extraction area reduces postoperative pain, facial swelling, and the risk of dry socket compared to standard healing.
Read the detailed description
This prospective, randomized, controlled clinical trial compares the efficacy of autologous platelet concentrates in reducing postoperative sequelae following the surgical extraction of impacted mandibular third molars.
A total of 42 patients were randomly assigned to one of three groups:
Control Group: Standard surgical extraction without additional biomaterials.
CGF Group: Standard extraction followed by the placement of a CGF clot into the extraction socket.
PRP Group: Standard extraction followed by submucosal injection of PRP.
The primary outcome measured is postoperative pain (Visual Analog Scale) on postoperative days 1, 3, and 7. The secondary outcomes include facial swelling (linear measurements) on postoperative days 1, 3, and 7, and the incidence of alveolar osteitis (dry socket).
- Conditions
- Impacted Third Molar
- Being tested
- Concentrated Growth Factor (CGF), Platelet-Rich Plasma (PRP)
- Keywords
- Third Molar Surgery, PRP, CGF
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Concentrated Growth Factor (CGF)Biological
Standard surgical extraction followed by the placement of a Concentrated Growth Factor (CGF) clot into the extraction socket immediately after tooth removal.
Platelet-Rich Plasma (PRP)Biological
Standard surgical extraction followed by submucosal injection of Platelet-Rich Plasma (PRP) around the extraction site.
| Study group | Role | What they receive |
|---|---|---|
| Control Group | No intervention | Standard surgical extraction was performed without the application of any additional biomaterials. |
| CGF Group | Experimental | Standard surgical extraction followed by the placement of a Concentrated Growth Factor (CGF) clot into the extraction socket. Receives: Biological: Concentrated Growth Factor (CGF) |
| PRP Group | Experimental | Standard surgical extraction followed by submucosal injection of Platelet-Rich Plasma (PRP). Receives: Biological: Platelet-Rich Plasma (PRP) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative Pain
Assessed using a Visual Analog Scale (VAS) ranging from 0 (no pain) to 10 (worst pain imaginable).
Measured: Postoperative days 1, 3, and 7.
Secondary outcomes (2)
Facial Swelling
Measured using linear distances between specific facial landmarks (tragus to mouth commissure, tragus to pogonion, lateral canthus to mandibular angulus) to evaluate edema.
Measured: Preoperative and Postoperative days 1, 3, and 7.
Incidence of Alveolar Osteitis
Evaluated based on clinical signs such as loss of blood clot, intense throbbing pain, and halitosis (dry socket).
Measured: Postoperative days 1, 3, and 7
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jan 2026
- Study start2 May 2024
- Primary completion2 May 2025
- Study completion2 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Impacted Third MolarStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 42 participants (actual)
Sponsor and investigators
- Lead sponsor
- Recep Tayyip Erdogan University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Emin Valiyev, Recep Tayyip Erdogan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07320170
- Sponsor's protocol ID
- 2024/52
- Status last verified
- Jan 2026
- First submitted
- 20 Dec 2025
- Last updated
- 8 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared.
Publications
Valiyev E, Dogan A. Effects of concentrated growth factor and platelet-rich plasma on postoperative pain and edema following impacted mandibular third molar surgery: a randomized controlled clinical trial. BMC Oral Health. 2026 Jun 29. doi: 10.1186/s12903-026-09054-3. Online ahead of print.
PubMed 42374377
Study at a glance
From the registry record, last updated by the sponsor on 8 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Effects of Platelet-rich Plasma and Concentrated Growth Factor on Postoperative Pain, Swelling, and Alveolar Osteitis After Mandibular Third Molar Surgery: a Randomized Controlled Clinical Trial
- ClinicalTrials.gov ID
- NCT07320170
- Acronym / sponsor ID
- 2024/52
- Conditions
- Impacted Third Molar
- Keywords
- Third Molar Surgery, PRP, CGF
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 42 participants (actual)
- Lead sponsor
- Recep Tayyip Erdogan UniversityUniversity, hospital or other
- Study start
- 2 May 2024 (actual)
- Primary completion
- 2 May 2025 (actual)
- Study completion
- 2 May 2025 (actual)
- First posted
- 6 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates the effects of two different blood products obtained from the patient's own blood (Concentrated Growth Factor [CGF] and Platelet-Rich Plasma [PRP]) on healing after wisdom tooth extraction. The aim is to determine whether applying these materials to the extraction area reduces postoperative pain, facial swelling, and the risk of dry socket compared to standard healing.
Detailed description
This prospective, randomized, controlled clinical trial compares the efficacy of autologous platelet concentrates in reducing postoperative sequelae following the surgical extraction of impacted mandibular third molars.
A total of 42 patients were randomly assigned to one of three groups:
Control Group: Standard surgical extraction without additional biomaterials.
CGF Group: Standard extraction followed by the placement of a CGF clot into the extraction socket.
PRP Group: Standard extraction followed by submucosal injection of PRP.
The primary outcome measured is postoperative pain (Visual Analog Scale) on postoperative days 1, 3, and 7. The secondary outcomes include facial swelling (linear measurements) on postoperative days 1, 3, and 7, and the incidence of alveolar osteitis (dry socket).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Control Group | No intervention | –Standard surgical extraction was performed without the application of any additional biomaterials. |
| CGF Group | Experimental | Biological: Concentrated Growth Factor (CGF)Standard surgical extraction followed by the placement of a Concentrated Growth Factor (CGF) clot into the extraction socket. |
| PRP Group | Experimental | Biological: Platelet-Rich Plasma (PRP)Standard surgical extraction followed by submucosal injection of Platelet-Rich Plasma (PRP). |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Patients aged between 18 and 50 years.
- Systemically healthy individuals classified as American Society of Anesthesiologists (ASA) Class I or Class II.
- Presence of impacted mandibular third molars (teeth 38 and 48 according to Fédération Dentaire Internationale (FDI) notation).
- Mesioangular impaction with bone retention according to Winter's classification.
- Class II relationship to the ramus according to the Pell and Gregory classification.
Key exclusion criteria (10 listed)
- Patients younger than 18 years.
- Habitual smoking or alcohol consumption.
- Presence of coagulation (bleeding) disorders.
- Systemic diseases affecting wound healing or use of medications that compromise healing.
- Pregnancy or lactation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Concentrated Growth Factor (CGF)Standard surgical extraction followed by the placement of a Concentrated Growth Factor (CGF) clot into the extraction socket immediately after tooth removal. | Biological | CGF Group |
| Platelet-Rich Plasma (PRP)Standard surgical extraction followed by submucosal injection of Platelet-Rich Plasma (PRP) around the extraction site. | Biological | PRP Group |
Primary outcome
Postoperative Pain
Time frame: Postoperative days 1, 3, and 7.
Assessed using a Visual Analog Scale (VAS) ranging from 0 (no pain) to 10 (worst pain imaginable).
2 secondary outcomes
Facial Swelling
Time frame: Preoperative and Postoperative days 1, 3, and 7.
Incidence of Alveolar Osteitis
Time frame: Postoperative days 1, 3, and 7
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jan 2026.
- Derived from this study: PubMed 42374377Valiyev E, Dogan A. Effects of concentrated growth factor and platelet-rich plasma on postoperative pain and edema following impacted mandibular third molar surgery: a randomized controlled clinical trial. BMC Oral Health. 2026 Jun 29. doi: 10.1186/s12903-026-09054-3. Online ahead of print.
- Individual participant dataSharing planned: No. Individual participant data will not be shared.
Related trials for Impacted Third Molar
Recruiting
Aescin-Based Herbal Extract (Reparil) for Postoperative Sequelae After Mandibular Third Molar Surgery
Postoperative Pain, Facial Swelling
Recruiting
Effect of Collagen Membranes on Distal Periodontal Healing of Second Molars After Impacted Mandibular Third Molar Surgery.
Periodontal Defect
RecruitingObservational study
Oral Specimen and Data Acquisition Study of Subjects Requiring Third Molar Removal
Stomatognatic, Tooth Diseases
Recruiting
Effect of Alpha-Band Binaural Beats on Stress and Recovery in Third Molar Surgery
Dental Anxiety, Postoperative Pain
Not yet recruiting
Antibacterial Effect and Soft Tissue Healing of Chlorhexidine-Coated Polyglactin 910 Sutures After Impacted Lower Third Molar Surgery
Impacted Third Molar Tooth, Surgical Wound Healing
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Concentrated Growth Factor (CGF) and Platelet-Rich Plasma (PRP) in people with Impacted Third Molar, run by Recep Tayyip Erdogan University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postoperative Pain (time frame: Postoperative days 1, 3, and 7.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07320170, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jan 2026.